Estimates Revisions Candel Therapeutics, Inc.
Stocks
CADL
US1374041093
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
16:00:00 2026-08-24 EDT
|
5-day change | 1st Jan Change | ||
| 12.86 USD | -2.06% |
|
+5.76% | +127.61% |
| 08-14 | BofA Adjusts Price Target on Candel Therapeutics to $12 From $9 | MT |
| 08-13 | Candel Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| - | |||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
- Stock Market
- Stocks
- CADL Stock
- Consensus Candel Therapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
